Latest Clinical trial Stories
IRVINE, Calif., Jan. 8, 2013 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced that Joan E. Shaw, MT (ASCP), SCC has joined the Company as Senior Director of Clinical Operations. "We are pleased to announce that Joan Shaw has recently joined AtheroNova's management team, adding another integral part to the staffing...
CLEVELAND, Jan. 7, 2013 /PRNewswire/ -- DATATRAK International, Inc. (OTCQX: DATA), a leader in developing cloud-based, unified eClinical® technologies and delivering related services for the clinical trials industry, today announced it will soon be trading as DTRK. The new symbol more closely aligns with the company name and will be active January 9, 2013. (Logo: http://photos.prnewswire.com/prnh/20130107/CL38347LOGO ) "Changing our stock symbol is just one small part of...
Alan McStravick for redOrbit.com - Your Universe Online Peanuts are one of the most common triggers of severe food-induced allergic reactions. In many instances, this reaction can even be fatal. Add to that recent studies showing that the overall prevalence of peanut allergies has been steadily on the rise, not to mention the fact that the danger of this allergy is magnified by the fact there is currently no clinical treatment for its sufferers short of strict dietary abstinence. A new...
BUFFALO, N.Y., Jan. 7, 2013 /PRNewswire/ -- Kinex Pharmaceuticals and Hanmi Pharmaceutical announced today that the first patient has been enrolled in Hanmi's Phase Ib / IIa clinical trial in Korea. Kinex's dual Src/pretubulin Inhibitor, KX01, is being combined with intravenous (IV) paclitaxel to treat solid tumor patients in Phase Ib and then gastric and breast cancer patients in Phase IIa. KX01 (KX2-391) is an once daily, orally administered potent small molecule Src...
SAN DIEGO, Jan. 7, 2013 /PRNewswire/ -- Orexigen(®) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced progress with the United States Food and Drug Administration (FDA) on a faster path to resubmission of the Contrave(®) (naltrexone SR / bupropion SR) New Drug Application (NDA). Consistent with the spirit of the formal dispute resolution request (FDRR) response letter issued to the Company in October by the...
LYNBROOK, N.Y., Jan. 7, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX® in Europe and Eurasia, today announced progress for XIAFLEX in two pipeline indications. BioSpecifics' strategic partner Auxilium Pharmaceuticals, Inc. (Auxilium) has exercised its exclusive option under the Second Amended and Restated Development and License Agreement...
NES-ZIONA, Israel, Jan. 7, 2013 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced that it received a notice of allowance from the U.S. Patent and Trademark Office for a patent application covering the company's CTP platform, which has the potential to extend the duration of activity of therapeutic proteins. The allowed claims cover manufacturing methods for CTP-modified compositions of a wide array of classes of therapeutic proteins, including hormones, high...
ROCKVILLE, Md., Jan. 7, 2013 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that EntreMed has submitted a new drug clinical trial application with China's State Food and Drug Administration (SFDA) for its proprietary drug candidate, ENMD-2076, to conduct global clinical trials in triple-negative breast cancer patients. (Logo:...
PLYMOUTH, Mich., Jan 7, 2013 /PRNewswire/ -- Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced positive results of a recently completed Phase 2 clinical trial of ETC-1002 in patients with type 2 diabetes with LDL-C lowering of up to 43% compared to placebo. ETC-1002 therapy was also associated with improvements in control of additional cardiometabolic risk factors in this high-risk,...
MOUNTAIN VIEW, Calif., Jan. 7, 2013 /PRNewswire/ -- Edison Pharmaceuticals today announced the initiation of a phase 2B study entitled, "Safety and Efficacy Study of EPI-743 on Visual Function in Patients with Friedreich's Ataxia." The trial is a placebo-controlled study lasting six months, followed by an extension phase in which all subjects will receive EPI-743. Subjects must be between 18 and 45 years of age, possess genetic confirmation of Friedreich's ataxia, and meet...
